Table 1 Maternal characteristics at baseline for the neurocognitive analysis population. Continuous variables are presented as median (25th, 75th percentile), and categorical variables are presented as N (%) or N/Total N (%) for variables with missing values
Immediate INH (N = 370) | Deferred INH (N = 379) | Overall (N = 749) | ||
|---|---|---|---|---|
Age (years) | Median (25th, 75th) | 29.0 (25.0, 33.0) | 29.0 (24.0, 34.0) | 29.0 (24.0, 33.0) |
16—< 20 | 14 (4) | 17 (4) | 31 (4) | |
20—< 24 | 61 (16) | 69 (18) | 130 (17) | |
≥ 24 | 295 (80) | 293 (77) | 588 (79) | |
Self-reported race/ethnicity | Black African | 337 (91) | 335 (88) | 672 (90) |
Black of African origin | 7 (2) | 12 (3) | 19 (3) | |
Indian or South Asian | 13 (4) | 13 (3) | 26 (3) | |
Thai | 8 (2) | 12 (3) | 20 (3) | |
Other Asian | 5 (1) | 7 (2) | 12 (2) | |
Country | Botswana | 29 (8) | 30 (8) | 59 (8) |
Haiti | 7 (2) | 12 (3) | 19 (3) | |
India | 13 (4) | 13 (3) | 26 (3) | |
South Africa | 65 (18) | 63 (17) | 128 (17) | |
Tanzania | 32 (9) | 33 (9) | 65 (9) | |
Thailand | 13 (4) | 18 (5) | 31 (4) | |
Uganda | 68 (18) | 64 (17) | 132 (18) | |
Zimbabwe | 143 (39) | 146 (39) | 289 (39) | |
Gestational age (weeks) | 14—< 24 | 130 (35) | 136 (36) | 266 (36) |
24—34 | 240 (65) | 243 (64) | 483 (64) | |
HIV-1 RNA (copies/mL) | Undetectable | 226 (61) | 241 (64) | 467 (62) |
CD4 count (cells/mm3) | Median (25th, 75th) | 495 (348, 679) | 505 (367, 703) | 499 (355, 689) |
BMI (kg/m2) | Median (25th, 75th) | 26.3 (23.4, 30.3) | 26.1 (23.1, 29.5) | 26.2 (23.3, 29.9) |
WHO clinical staging for HIV | Clinical stage I | 327 (88) | 331 (87) | 658 (88) |
IGRA positivity | Positive | 104/363 (29) | 114/373 (31) | 218/736 (30) |
Negative | 235/363 (65) | 233/373 (62) | 468/736 (64) | |
Indeterminate | 24/363 (7) | 26/373 (7) | 50/736 (7) | |
HBsAg serology | Positive | 12 (3) | 14 (4) | 26 (3) |
Hepatitis C serology | Positive | 5/345 (1) | 4/353 (1) | 9/698 (1) |
INH acetylation status | Fast | 59/361 (16) | 58/348 (17) | 117/709 (17) |
Intermediate | 139/361 (39) | 140/348 (40) | 279/709 (39) | |
Slow | 163/361 (45) | 150/348 (43) | 313/709 (44) | |
EFV metabolism status | Fast | 89/358 (25) | 91/363 (25) | 180/721 (25) |
Intermediate | 191/358 (53) | 194/363 (53) | 385/721 (53) | |
Slow | 78/358 (22) | 78/363 (21) | 156/721 (22) | |
Cotrimoxazole use | Yes | 179/369 (48) | 164/378 (43) | 343/747 (46) |
ARV regimen | EFV | 313 (85) | 327 (86) | 640 (85) |
NVP | 46 (12) | 46 (12) | 92 (12) | |
Other | 11 (3) | 6 (2) | 17 (2) | |
Duration of EFV-containing regimen prior to entry (weeks)a | Median (25th, 75th) | 10.0 (3.0, 41.0) | 9.0 (3.0, 30.0) | 9.0 (3.0, 38.5) |